🇺🇸 FDA
Pipeline program

Famitinib

HR-FMTN- Ⅱ-NSCLC-MON

Phase 2 small_molecule on_hold

Quick answer

Famitinib for Non-Small Cell Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Non-Small Cell Lung Cancer (NSCLC)
Phase
Phase 2
Modality
small_molecule
Status
on_hold

Clinical trials